002644 佛慈制药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.2322.7173.3983.8796.519
总资产报酬率 ROA (%)0.8871.9622.4042.6174.383
投入资产回报率 ROIC (%)1.1502.5753.2213.5785.991

边际利润分析
销售毛利率 (%)37.12734.09130.57631.06229.280
营业利润率 (%)12.8217.2077.1877.16013.732
息税前利润/营业总收入 (%)12.1996.5676.5286.59111.809
净利润/营业总收入 (%)10.8105.1296.2915.85710.490

收益指标分析
经营活动净收益/利润总额(%)105.351156.361110.620102.84470.529
价值变动净收益/利润总额(%)-7.472-20.817-10.462-5.501-0.992
营业外收支净额/利润总额(%)-0.341-1.469-1.889-2.000-9.509

偿债能力分析
流动比率 (X)3.0443.0253.2182.6492.403
速动比率 (X)2.3882.3672.3221.8581.734
资产负债率 (%)27.10727.16526.51330.04933.195
带息债务/全部投入资本 (%)-5.720-5.617-11.232-8.628-8.598
股东权益/带息债务 (%)-1,634.762-1,658.369-859.139-1,078.540-1,063.428
股东权益/负债合计 (%)265.563264.824273.346229.753198.687
利息保障倍数 (X)-21.091-12.258-12.421-15.412-16.152

营运能力分析
应收账款周转天数 (天)133.045120.043109.100103.742110.313
存货周转天数 (天)197.441187.880187.723164.541151.898